News/ News/ R&D Vifor, Angion organ damage drug fails phase 3 kidney transplant study Phil Taylor Angion Biomedica, nephrology, transplant, Vifor Pharma 0 Comment Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this Share X Vifor, Angion organ damage drug fails phase 3 kidney transplant study https://pharmaphorum.com/news/vifor-angion-organ-damage-drug-fails-phase-3-kidney-transplant-study/
Angion Biomedica, nephrology, transplant, Vifor Pharma
0 Comment
